|
In this edition, Francesca T. Aweeka, PharmD, and Andrew R. Zolopa, MD, provide a pharmacologist’s and a clinician’s perspective on the potential interaction between etravirine and raltegravir; Kimberly Y. Smith, MD, MPH, explains how recently published data from the NA-ACCORD may affect clinical practice; Robert M. Grant, MD, MPH, describes a prevention strategy that involves use of antiretroviral agents to block transmission of HIV-1 to persons at high risk; Robert F. Siliciano, MD, PhD, discusses his research on the inhibitory potential of antiretroviral drugs with Andrew R. Zolopa, MD; and Lisa Capaldini, MD, shares her approach to determining when to initiate antiretroviral therapy in her patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
-
Cite strengths and weaknesses of 4 case reports of a potential interaction between etravirine and raltegravir
-
Discuss data from the NA-ACCORD that suggest a clinical benefit associated with initiation of antiretroviral therapy at CD4+ cell counts > 500 cells/mm3
-
Explain the potential clinical utility of determining the slope parameter for antiretroviral agents
-
Specify some patient-specific barriers to early treatment of HIV infection
CCO Video Module contain video commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.
|
Program Directors
-
|
Kimberly Y. Smith
MD, MPH
|
|
Kathleen E. Squires
MD
|
|
Andrew R. Zolopa
MD
|
Faculty
-
|
|
Francesca T. Aweeka
PharmD
|
|
|
Lisa Capaldini
MD
|
|
|
Robert M. Grant
MD, MPH
|
|
|
Robert F. Siliciano
MD, PhD
|
Credit Information
|